Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Elacestrant

Elacestrant (RAD1901) is an orally available and selective estrogen receptor degrader (SERD) with IC50s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant also can inhibit growth of ER+ breast cancer cell lines in vitro and in vivo[1][2].

Product Specifications

CAS Number

[722533-56-4]

Product Name Alternative

RAD1901

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

Estrogen Receptor/ERR

Type

Reference compound

Related Pathways

Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Elacestrant.html

Concentration

10mM

Purity

99.38

Solubility

DMSO : 160 mg/mL (ultrasonic)

Smiles

OC1=CC=C2C[C@H](C3=CC=C(OC)C=C3N(CC)CC4=CC=C(CCNCC)C=C4)CCC2=C1

Molecular Formula

C30H38N2O2

Molecular Weight

458.63

Precautions

H302, H312, H332

References & Citations

[1]Garner F, et al. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs. 2015 Oct;26 (9) :948-56.|[2]Bihani T, et al. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models. Clin Cancer Res. 2017 Aug 15;23 (16) :4793-4804.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture and light)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

Biomed Pharmacother. 2024 Nov:180:117523.|bioRxiv. 2023 Nov 2.|bioRxiv. 2024 Jun 2:2024.05.28.596307.|bioRxiv. 2025 Nov 21:2025.11.20.689560.|Genes Dev. 2025 Nov 5.|Harvard University. 2023 Mar. 30487357.|J Cell Mol Med. 2023 Sep;27 (17) :2467-2481.|NPJ Breast Cancer. 2022 Dec 14;8 (1) :130.|NPJ Breast Cancer. 2025 Nov 12;11 (1) :125.|Res Sq. 2024 Jun 04.|Research Square Preprint. 2023 May 9.|Research Square Preprint. 2024 Nov 06.|Cancer Discov. 2024 Feb 8;14 (2) :274-289.|Cancer Res. 2024 Dec 16;84 (24) :4283-4297.|J Med Chem. 2020 Oct 8;63 (19) :11085-11099.|Mol Cancer Ther. 2020 Jul;19 (7) :1395-1405.

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

APC Linked Polyclonal Antibody to Poly/rC Binding Protein 1 (PCBP1)

MBS2136730-01 0.1 mL

APC Linked Polyclonal Antibody to Poly/rC Binding Protein 1 (PCBP1)

Ask

APC Linked Polyclonal Antibody to Poly/rC Binding Protein 1 (PCBP1)

MBS2136730-02 0.2 mL

APC Linked Polyclonal Antibody to Poly/rC Binding Protein 1 (PCBP1)

Ask

APC Linked Polyclonal Antibody to Poly/rC Binding Protein 1 (PCBP1)

MBS2136730-03 0.5 mL

APC Linked Polyclonal Antibody to Poly/rC Binding Protein 1 (PCBP1)

Ask

APC Linked Polyclonal Antibody to Poly/rC Binding Protein 1 (PCBP1)

MBS2136730-04 1 mL

APC Linked Polyclonal Antibody to Poly/rC Binding Protein 1 (PCBP1)

Ask

APC Linked Polyclonal Antibody to Poly/rC Binding Protein 1 (PCBP1)

MBS2136730-05 5 mL

APC Linked Polyclonal Antibody to Poly/rC Binding Protein 1 (PCBP1)

Ask

APC Linked Polyclonal Antibody to Poly/rC Binding Protein 1 (PCBP1)

MBS2136730-06 5x 5 mL

APC Linked Polyclonal Antibody to Poly/rC Binding Protein 1 (PCBP1)

Ask